Biotechnology

Genflow Biosciences PLC Announces Receipt of Grant Funding

June 12, 2024 2:00 AM

LONDON, UK / ACCESSWIRE / June 12, 2024 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC...

Read more

Auxilius Revenue Grows 800% in 2023, Raises $10M to Scale Clinical Trial Financial Management Platform

June 11, 2024 4:45 PM

Rapid growth and strong partnerships with over 50 innovative biopharma companies power Auxilius's momentum ahead of its latest fundraise NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Auxilius, the first Clinical Trial Financial Management (CTFM) software which enables life science finance, accounting, and clinical operations teams to automate accounting workflows and improve clinical R&D forecast accuracy, has raised $10M in additional financing,...

Read more

Next Gen Diagnostics Announces Opening of a US Sequencing and Bioinformatics Laboratory in Cambridge, Massachusetts

June 11, 2024 12:00 PM

WEST PALM BEACH, FL / ACCESSWIRE / June 11, 2024 / Next Gen Diagnostics announces its first US laboratory will be opening in Cambridge, Massachusetts, to provide low-cost, fully integrated bacterial sequencing and bioinformatics to US customers and partners. Leveraging the advantages of its NGD100 high throughput microfluidic sequencing sample preparation instrument and automated pathogen bioinformatics systems, NGD offers sequencing combined...

Read more

KeViRx, Inc. Awarded $1.99 Million

June 11, 2024 10:15 AM

Department of Defense grant will advance small molecule technology for acute lung injury CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2024 / KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense's Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology,...

Read more

Biolog Delves Into Characterizing Gut Microbiomes With the Launch of PreBioM Plates

June 11, 2024 5:00 AM

HAYWARD, CA / ACCESSWIRE / June 11, 2024 / Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic profiling products and services, is excited to announce the launch of its new PreBioM™ microplate product line for microbiome analysis and organism selection. These microplates are designed to enable phenotypic characterization of individual organisms and communities typically found in the gut microbiome, providing...

Read more

Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference

June 10, 2024 9:15 AM

Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET. As part of the event, Roelof Rongen, CEO of Adolore, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and...

Read more

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

June 10, 2024 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports positive results from its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene that easily adheres inside of the mouth on the cheek and biodegrades within minutes. Results in...

Read more

Next Gen Diagnostics CEO Paul Rhodes Announces That Dr. Linoj Samuel Has Joined NGD’s Scientific Advisory Board

June 7, 2024 3:00 PM

WEST PALM BEACH, FL / ACCESSWIRE / June 7, 2024 / Next Gen Diagnostics announces that Dr. Linoj Samuel, Division Head of the Clinical Microbiology Laboratory for Henry Ford Health in Detroit Michigan, has joined NGD's Scientific Advisory Board. Dr. Samuel, a national leader in defining best practices for integration of clinical microbiology results to optimally benefit patient care and hospital function, is also the current Chair of the American...

Read more

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

June 6, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose, today announced the achievement of a critical milestone in its opioid use disorder (OUD) program with the selection of a lead drug candidate to move into Investigational...

Read more

InDevR and Sino Biological Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy

June 5, 2024 11:00 AM

Partnership addresses biopharmaceutical industry's urgent need for improved in-process and QC testing tools for these rapidly evolving application fields BOULDER, CO / ACCESSWIRE / June 5, 2024 / InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047) specializing in biological...

Read more

DPH Biologicals Delivers Next Generation Biologicals with Expanded Portfolio Built on Novel Technology Platform

June 4, 2024 9:00 AM

DPH Biologicals, a leading developer and supplier of agricultural biologicals, announced its new Prime platform that uses a patented production process for Bacillus spp., a leading plant growth rhizobacterium, to accelerate the germination of bacteria spores, supporting overall plant development while providing crops with more consistent resilience against heat, drought, and alkaline and saline soil conditions. "Historically biologicals have...

Read more

Data4Cure to Present at the BIO International Convention 2024

June 3, 2024 9:00 PM

WALTHAM, MA / ACCESSWIRE / June 3, 2024 / Data4Cure, a leading biomedical data-to-knowledge company, today announced its upcoming presentation at the BIO International Convention 2024 taking place June 3-6, 2024, in San Diego, California. Data4Cure's CEO Dr. Janusz Dutkowski will present advances in the company's Biomedical Intelligence Cloud platform powered by a continuously updated data-driven knowledge graph of over three billion relations....

Read more

PharmaNest to Present Seven Digital Pathology and AI Communications and Abstracts at the International Liver Congress — EASL 2024, Including Analytical and Clinical Validation

June 3, 2024 9:00 AM

PharmaNest, a leader in high-resolution, single-fiber quantitative Digital Pathology and Artificial Intelligence, showcases the performance of its FibroNest Ph-FCS digital biomarker for quantifying fibrosis severity and its clinical utility in Phase 2 and Phase 3 studies for patients with Metabolic Associated Steatohepatitis (MASH). PRINCETON, NJ / ACCESSWIRE / June 3, 2024 / PharmaNest Inc., a leader in high-resolution quantitative Digital...

Read more

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

June 3, 2024 8:35 AM

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks Eighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or avelumab therapy achieved a durable Complete Response (CR), pathologic CR or Partial Response (PR) following IFx-2.0 therapy and rechallenge with an anti-PD(L)-1 checkpoint inhibitor Data presented at the 2024 American Society of Clinical Oncology...

Read more

Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology

June 3, 2024 2:20 AM

LUND, SE / ACCESSWIRE / June 03, 2024 / Alligator Bioscience (STO:ATORX) Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 results The study reported Objective Response Rate (ORR) of 40.4% in 57 evaluable patients, primary endpoint was met. The novel combination of mitazalimab and mFOLFIRINOX and the unique dosing schedule resulted in an unprecedented Duration of...

Read more

Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference

May 31, 2024 12:30 PM

NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC. Dane Andreeff, CEO, will attend the conference and plans to discuss: Pursuit of a stroke...

Read more

InnoSIGN Launches New Suite Products for Pharmaceutical Research and Clinical Studies

May 31, 2024 9:00 AM

Analysis of aberrant pathway signaling provides the greatest insight into targeted therapies MASON, OH and EINDHOVEN, THE NETHERLANDS / ACCESSWIRE / May 31, 2024 / InnoSIGN, a life sciences company committed to advancing precision medicine through a proprietary, innovative platform that identifies the true drivers of disease, today announced that it has launched a suite of products and services with this platform directed at supporting...

Read more

Increase of Number of Shares and Votes in Vicore Pharma

May 31, 2024 3:20 AM

STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to a participant in the incentive program Board LTIP 2023. The shares were issued through the exercise of 11,025 share rights, which are entitled to an...

Read more

New Research Study Reveals Critical Role of Magnesium in Regulating Brain Synapses and Cognition

May 30, 2024 12:00 PM

High Levels of Intracellular Magnesium Promote a Large Number of Weak Synaptic Configurations, Optimal for Encoding New Information and Learning WALNUT CREEK, CA. / ACCESSWIRE / May 30, 2024 / Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD) and other neurodegenerative and neuropsychiatric...

Read more

BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's Lead Candidates BI-1808 and BI-1206

May 30, 2024 8:30 AM

BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a virtual KOL event on Tuesday, June 18,...

Read more